PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
Authors:
- Jonathan J. HodginsJHJonathan J. Hodgins
- John Abou-HamadJAJohn Abou-Hamad
- Colin Edward O’dWyerCOColin Edward O’dWyer
- Ash HagermanAHAsh Hagerman
- Edward YakubovichEYEdward Yakubovich
- Christiano Tanese de SouzaCSChristiano Tanese de Souza
- Marie MarotelMMMarie Marotel
- Ariel BuchlerABAriel Buchler
- Saleh FadelSFSaleh Fadel
- Maria M. ParkMPMaria M. Park
- Claire Fong-McMasterCFClaire Fong-McMaster
- Mathieu F. CrupiMCMathieu F. Crupi
Open Access
- 13 June 2024
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (7)
Abstract
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1–expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo. Consistently, PD-L1 expression marked tumor explants from cancer patients that were best infected by oncolytic viruses. Mechanistically, PD-L1 promoted a metabolic shift characterized by enhanced glycolysis rate that resulted in increased lactate production. In turn, lactate inhibited type I IFN responses. In addition to adding mechanistic insight into PD-L1 intrinsic function, our results will also help guide the numerous ongoing efforts to combine PD-L1 antibodies with oncolytic virotherapy in clinical trials.Keywords
Funding Information
- Canadian Institutes of Health Research
- Ride for Dad
- Cancer Research Society
- Charles Best Canada Graduate Scholarships Doctoral
- Ontario Graduate Scholarship
- BioCanRX
- Canadian Allergy, Asthma, and Immunology Foundation
- University of Ottawa Heart Institute
- Schulich Leader Scholarship
- University of Ottawa
- Natural Sciences and Engineering Research Council of Canada
- Taggart-Parkes Fellowship
- CI3 scholarship
- Vanier Canada
- Canadian Cancer Society Research Institute
- Terry Fox Research Institute
- Canadian Fund for Innovation
- Terry Fox Foundation
- Prostate Cancer Canada
This publication has 90 references indexed in Scilit:
- Lactylation: a Passing Fad or the Future of Posttranslational ModificationInflammation, 2022
- STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancerClinical and Translational Oncology, 2022
- DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor ImmunityCancer Cell, 2020
- MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING PathwayCancer Cell, 2020
- Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic EfficacyCancer Cell, 2019
- Plate-Based Measurement of Respiration by Isolated Mitochondria2018
- Role of cellular metabolism in regulating type I interferon responses: Implications for tumour immunology and treatmentCancer Letters, 2017
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinomaMedical Oncology, 2015
- Propagation, Purification, and In Vivo Testing of Oncolytic Vesicular Stomatitis Virus Strains2011